Biological markers and schizophrenia

被引:16
作者
Copolov, D
Crook, J
机构
[1] Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia
[2] NIMH, Clin Brain Disorders Branch, Bethesda, MD 20892 USA
关键词
biological markers; dopamine; homovanillic acid; review; schizophrenia; smooth pursuit eye movements; ventricles;
D O I
10.1046/j.1440-1614.2000.00778.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The delivery of biological markers for schizophrenia would greatly assist preventative strategies by identifying at-risk individuals who could then be monitored and treated in a manner with a view to minimising subsequent morbidity. This paper aims to present a selection of biological measures that may indicate risk of schizophrenia. Method: A selective and brief review is provided of intensively studied putative markers, including enlarged cerebral ventricles, dopamine D-2 receptor density, amphetamine-stimulated central nervous system dopamine release, plasma homovanillic acid and smooth pursuit eye tracking dysfunction. Results: A number of biological measures have been reported to be correlated with schizophrenia. Conclusions: Presently, none of these measures has satisfactory performance characteristics in terms of predictive validity, noninvasiveness, ease of testing and low cost that would enable their widespread use. However, a few have potential for further investigation and development.
引用
收藏
页码:S108 / S112
页数:5
相关论文
共 48 条
[21]  
Kapur S, 1999, AM J PSYCHIAT, V156, P286
[22]   MULTIDIAGNOSTIC EVALUATION OF PROLACTIN RESPONSE TO HALOPERIDOL CHALLENGE IN SCHIZOPHRENIA - MAXIMAL BLUNTING IN KRAEPELINIAN PATIENTS [J].
KEKS, NA ;
MCKENZIE, DP ;
LOW, LH ;
MCGORRY, PD ;
HILL, C ;
KULKARNI, J ;
SINGH, BS ;
COPOLOV, DL .
BIOLOGICAL PSYCHIATRY, 1992, 32 (05) :426-437
[23]  
KENDELL RE, 1982, ARCH GEN PSYCHIAT, V39, P1334
[24]   PSYCHOMOTOR IMPAIRMENT AND COGNITIVE DISTURBANCES INDUCED BY NEUROLEPTICS [J].
KING, DJ .
ACTA PSYCHIATRICA SCANDINAVICA, 1994, 89 :53-58
[25]   ANALYSIS OF CEREBROSPINAL-FLUID MONOAMINES IN SCHIZOPHRENIC-PATIENTS ON AND OFF NEUROLEPTIC TREATMENT AND COMPARED WITH HEALTHY CONTROLS [J].
KIRCH, DG ;
SUDDATH, RL ;
GERHARDT, GA ;
ISSA, F ;
FREEDMAN, R ;
WYATT, RJ .
SCHIZOPHRENIA RESEARCH, 1991, 4 (03) :349-349
[26]   Heterogeneity of the psychoses: Is there a neurodegenerative psychosis? [J].
Knoll, JL ;
Garver, DL ;
Ramberg, JE ;
Kingsbury, SJ ;
Croissant, D ;
McDermott, B .
SCHIZOPHRENIA BULLETIN, 1998, 24 (03) :365-379
[27]  
Laruelle M, 1998, Q J NUCL MED, V42, P211
[28]   Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects [J].
Laruelle, M ;
Abi-Dargham, A ;
vanDyck, CH ;
Gil, R ;
DSouza, CD ;
Erdos, J ;
McCance, E ;
Rosenblatt, W ;
Fingado, C ;
Zoghbi, SS ;
Baldwin, RM ;
Seibyl, JP ;
Krystal, JH ;
Charney, DS ;
Innis, RB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (17) :9235-9240
[29]   Brain abnormality in schizophrenia - A systematic and quantitative review of volumetric magnetic resonance imaging studies [J].
Lawrie, SM ;
Abukmeil, SS .
BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 :110-120
[30]   Eye-tracking dysfunction (ETD) in families with sporadic and familial schizophrenia [J].
Lencer, R ;
Malchow, CP ;
Trillenberg-Krecker, K ;
Schwinger, E ;
Arolt, V .
BIOLOGICAL PSYCHIATRY, 2000, 47 (05) :391-401